Literature DB >> 4059652

Correlation of 2-PAM plasma levels after organophosphate intoxication.

M D Green, F Reid, A Kaminskis.   

Abstract

In order to investigate the pathophysiological effects of organophosphorus poisoning on therapeutic compounds, multiples of the LD50 for sarin and soman were injected into guinea pigs after which 2-PAM and atropine sulfate were administered intramuscularly. It was found that intoxication by sarin or soman in therapeutically treated animals resulted in modifications of plasma oxime concentrations. Peak plasma (CPmax) concentrations and areas under the curve (AUC) between 1 to 10 min after the injection of 2-PAM were altered in a systematic fashion which correlated to the multiple of the LD50 (r greater than 0.9498). The effect of the sarin and soman was studied at fractions of the LD50, i.e. 0.7s, 1.5, 2.2, 2.8, 5.6, 11.2. The influence of the organophosphorus poisons on the plasma concentration of 2-PAM is biphasic. Multiples of the LD50 equal to or below 2.2 tend to decrease, whereas multiples equal to or above 2.8 tend to increase CPmax and AUC in different groups of animals. Changes in the plasma concentrations of 2-PAM may result from alterations in blood flow rates and patterns which would alter the distribution and elimination of 2-PAM.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4059652

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  2 in total

1.  Receptor-mediated presynaptic facilitation of quantal release of acetylcholine induced by pralidoxime in Aplysia.

Authors:  P Fossier; G Baux; B Poulain; L Tauc
Journal:  Cell Mol Neurobiol       Date:  1990-09       Impact factor: 5.046

2.  Plasma concentrations of pralidoxime methylsulphate in organophosphorus poisoned patients.

Authors:  J L Willems; J P Langenberg; A G Verstraete; M De Loose; B Vanhaesebroeck; G Goethals; F M Belpaire; W A Buylaert; D Vogelaers; F Colardyn
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.